Ishii T - Search Results

1

A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.

Shimada N, Ishii T, Imada T, Takaba K, Sasaki Y, Maruyama-Takahashi K, Maekawa-Tokuda Y, Kusaka H, Akinaga S, Tanaka A, Shitara K. Shimada N, et al. Among authors: ishii t. Clin Cancer Res. 2005 May 15;11(10):3897-904. doi: 10.1158/1078-0432.CCR-04-2358. Clin Cancer Res. 2005. PMID: 15897591

2

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.

Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R. Ishida T, et al. Among authors: ishii t. Clin Cancer Res. 2004 Nov 15;10(22):7529-39. doi: 10.1158/1078-0432.CCR-04-0983. Clin Cancer Res. 2004. PMID: 15569983

3

Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.

Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Yano H, et al. Among authors: ishii t. Clin Cancer Res. 2007 Nov 1;13(21):6494-500. doi: 10.1158/1078-0432.CCR-07-1324. Clin Cancer Res. 2007. PMID: 17975162

4

A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.

Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A, Shitara K. Maruyama-Takahashi K, et al. Among authors: ishii t. Prostate. 2008 May 1;68(6):640-50. doi: 10.1002/pros.20728. Prostate. 2008. PMID: 18213631

5

Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R. Ishii T, et al. Clin Cancer Res. 2010 Mar 1;16(5):1520-31. doi: 10.1158/1078-0432.CCR-09-2697. Epub 2010 Feb 16. Clin Cancer Res. 2010. PMID: 20160057

6

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y. Nakashima T, et al. Among authors: ishii t. Clin Cancer Res. 2010 May 15;16(10):2792-802. doi: 10.1158/1078-0432.CCR-09-3112. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406843

7

Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer.

Kasai N, Sasakawa A, Hosomi K, Poh TW, Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K, Ishii T, Yamano K. Kasai N, et al. Among authors: ishii t. Am J Transl Res. 2017 Jul 15;9(7):3399-3410. eCollection 2017. Am J Transl Res. 2017. PMID: 28804556 Free PMC article.

8

An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, Poh TW, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R. Osanai-Sasakawa A, et al. Among authors: ishii t. Am J Cancer Res. 2018 Aug 1;8(8):1499-1513. eCollection 2018. Am J Cancer Res. 2018. PMID: 30210919 Free PMC article.

9

Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.

Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, Ishida T. Suzuki Y, et al. Among authors: ishii t. Clin Cancer Res. 2019 Jul 15;25(14):4388-4399. doi: 10.1158/1078-0432.CCR-18-2575. Epub 2019 Apr 24. Clin Cancer Res. 2019. PMID: 31018922

10

The dual pocket binding novel tankyrase inhibitor K-476 enhances the efficacy of immune checkpoint inhibitor by attracting CD8⁺ T cells to tumors.

Kinosada H, Okada-Iwasaki R, Kunieda K, Suzuki-Imaizumi M, Takahashi Y, Miyagi H, Suzuki M, Motosawa K, Watanabe M, Mie M, Ishii T, Ishida H, Saito JI, Nakai R. Kinosada H, et al. Among authors: ishii t. Am J Cancer Res. 2021 Jan 1;11(1):264-276. eCollection 2021. Am J Cancer Res. 2021. PMID: 33520373 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,484 results

Search Page

Filters